33 related articles for article (PubMed ID: 11063624)
1. Unconventional Site Selectivity in Palladium-Catalyzed Cross-Couplings of Dichloroheteroarenes under Ligand-Controlled and Ligand-Free Systems.
Norman JP; Larson NG; Entz ED; Neufeldt SR
J Org Chem; 2022 Jun; 87(11):7414-7421. PubMed ID: 35584051
[TBL] [Abstract][Full Text] [Related]
2. Charge Sensitive Optical Detection for Measurement of Small-Molecule Binding Kinetics.
Wang S; Ma G; Liang R; Tao N
Methods Mol Biol; 2022; 2393():315-328. PubMed ID: 34837187
[TBL] [Abstract][Full Text] [Related]
3. Azaindole synthesis through dual activation catalysis with N-heterocyclic carbenes.
Sharma HA; Todd Hovey M; Scheidt KA
Chem Commun (Camb); 2016 Jul; 52(59):9283-6. PubMed ID: 27363788
[TBL] [Abstract][Full Text] [Related]
4. Study of Small-Molecule-Membrane Protein Binding Kinetics with Nanodisc and Charge-Sensitive Optical Detection.
Ma G; Guan Y; Wang S; Xu H; Tao N
Anal Chem; 2016 Feb; 88(4):2375-9. PubMed ID: 26752355
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines.
Temburnikar KW; Ross CR; Wilson GM; Balzarini J; Cawrse BM; Seley-Radtke KL
Bioorg Med Chem; 2015 Aug; 23(15):4354-4363. PubMed ID: 26122770
[TBL] [Abstract][Full Text] [Related]
6. Efficient solution-phase synthesis of 4,5,7-trisubstituted pyrrolo[3,2-d]pyrimidines.
Zhang W; Liu J; Stashko MA; Wang X
ACS Comb Sci; 2013 Jan; 15(1):10-9. PubMed ID: 23181516
[TBL] [Abstract][Full Text] [Related]
7. NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs.
MacNeil DJ
Curr Top Med Chem; 2007; 7(17):1721-33. PubMed ID: 17979781
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
Torrens A; Mas J; Port A; Castrillo JA; Sanfeliu O; Guitart X; Dordal A; Romero G; Fisas MA; Sánchez E; Hernández E; Pérez P; Pérez R; Buschmann H
J Med Chem; 2005 Mar; 48(6):2080-92. PubMed ID: 15771450
[TBL] [Abstract][Full Text] [Related]
9. Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds.
Sakamoto T; Moriya M; Tsuge H; Takahashi T; Haga Y; Nonoshita K; Okamoto O; Takahashi H; Sakuraba A; Hirohashi T; Shibata T; Kanno T; Ito J; Iwaasa H; Gomori A; Ishihara A; Fukuroda T; Kanatani A; Fukami T
Bioorg Med Chem; 2009 Jul; 17(14):5015-26. PubMed ID: 19525116
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists.
Gillman KW; Higgins MA; Poindexter GS; Browning M; Clarke WJ; Flowers S; Grace JE; Hogan JB; McGovern RT; Iben LG; Mattson GK; Ortiz A; Rassnick S; Russell JW; Antal-Zimanyi I
Bioorg Med Chem; 2006 Aug; 14(16):5517-26. PubMed ID: 16697206
[TBL] [Abstract][Full Text] [Related]
11. Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.
Takahashi T; Haga Y; Sakamoto T; Moriya M; Okamoto O; Nonoshita K; Shibata T; Suga T; Takahashi H; Hirohashi T; Sakuraba A; Gomori A; Iwaasa H; Ohe T; Ishihara A; Ishii Y; Kanatani A; Fukami T
Bioorg Med Chem Lett; 2009 Jul; 19(13):3511-6. PubMed ID: 19464889
[TBL] [Abstract][Full Text] [Related]
12. Neuropeptide Y Y5 receptor antagonists as anti-obesity drugs.
Levens NR; Della-Zuana O
Curr Opin Investig Drugs; 2003 Oct; 4(10):1198-204. PubMed ID: 14649211
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists.
Norman MH; Chen N; Chen Z; Fotsch C; Hale C; Han N; Hurt R; Jenkins T; Kincaid J; Liu L; Lu Y; Moreno O; Santora VJ; Sonnenberg JD; Karbon W
J Med Chem; 2000 Nov; 43(22):4288-312. PubMed ID: 11063624
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
